Printsevskaya Svetlana S, Pavlov Andrey Y, Olsufyeva Evgenia N, Mirchink Elena P, Isakova Elena B, Reznikova Marina I, Goldman Robert C, Branstrom Arthur A, Baizman Eugene R, Longley Clifford B, Sztaricskai Ferenc, Batta Gyula, Preobrazhenskaya Maria N
Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, B. Pirogovskaya 11, Moscow, 119867 Russia.
J Med Chem. 2002 Mar 14;45(6):1340-7. doi: 10.1021/jm010460i.
Des-(N-methyl-D-leucyl)eremomycin was obtained by Edman degradation of eremomycin. Derivatives with a hydrophobic substituent at the exterior of the molecule were then synthesized, and their antibacterial activities were compared with similar derivatives of eremomycin. Comparison of derivatives of eremomycin containing the n-decyl or p-(p-chlorophenyl)benzyl substituent in the eremosamine moiety (N') and n-decyl or p-(p-chlorophenyl)benzylamides with similar derivatives of eremomycin possessing the damaged peptide core (a defective binding pocket) showed that compounds of both types are almost equally active against glycopeptide-resistant strains of enterococci (GRE), whereas eremomycin derivatives are more active against staphylococci. Hydrophobic 7d-alkylaminomethylated derivatives of eremomycin (9, 10) demonstrated similar antibacterial properties. Since the basic mode of action of glycopeptide antibiotics involves binding to cell wall intermediates terminating in -D-Ala-D-Ala and this interaction is seriously decreased in the hexapeptide derivatives (lacking the critical N-methyl-D-leucine), we suggest that these hydrophobic derivatives may inhibit peptidoglycan synthesis in the absence of dipeptide binding. NMR binding experiments using Ac-D-Ala-D-Ala show that binding constants of these hexapeptide derivativies are decreased in comparison with the corresponding heptapeptides with intact binding pocket. This is in agreement with the decreased biological activity of the hexapeptide derivatives against vancomycin-sensitive strains in comparison with the activity of parent compounds. Binding to the lactate cell wall analogue Ac-D-Ala-D-Lac with decylamide of eremomycin 8 was not observed, demonstrating that the interaction with this target in GRE does not occur. While hydrophobic glycopeptide derivatives retain the ability to inhibit the synthesis of peptidoglycan in manner of natural glycopeptides, biochemical investigation supports the hypothesis that they inhibit the transglycosylase stage of bacterial peptidoglycan biosynthesis even in the absence of dipeptide or depsipeptide binding.
去(N-甲基-D-亮氨酰基)埃瑞莫霉素是通过对埃瑞莫霉素进行埃德曼降解获得的。然后合成了在分子外部带有疏水取代基的衍生物,并将它们的抗菌活性与埃瑞莫霉素的类似衍生物进行了比较。对在埃瑞莫胺部分(N')含有正癸基或对(对氯苯基)苄基取代基的埃瑞莫霉素衍生物以及与具有受损肽核心(有缺陷的结合口袋)的埃瑞莫霉素类似衍生物的正癸基或对(对氯苯基)苄基酰胺进行比较,结果表明这两种类型的化合物对耐糖肽肠球菌(GRE)的活性几乎相同,而埃瑞莫霉素衍生物对葡萄球菌的活性更高。埃瑞莫霉素的疏水7d-烷基氨基甲基化衍生物(9,10)表现出类似的抗菌特性。由于糖肽抗生素的基本作用方式涉及与以-D-Ala-D-Ala结尾的细胞壁中间体结合,而这种相互作用在六肽衍生物(缺乏关键的N-甲基-D-亮氨酸)中严重降低,我们认为这些疏水衍生物可能在没有二肽结合的情况下抑制肽聚糖合成。使用Ac-D-Ala-D-Ala进行的NMR结合实验表明,与具有完整结合口袋的相应七肽相比,这些六肽衍生物的结合常数降低。这与六肽衍生物相对于母体化合物对万古霉素敏感菌株的生物活性降低是一致的。未观察到埃瑞莫霉素8的癸酰胺与乳酸细胞壁类似物Ac-D-Ala-D-Lac的结合,这表明在GRE中与该靶点的相互作用不会发生。虽然疏水糖肽衍生物保留了以天然糖肽的方式抑制肽聚糖合成的能力,但生化研究支持这样的假设,即它们即使在没有二肽或缩肽结合的情况下也能抑制细菌肽聚糖生物合成的转糖基酶阶段。